Quality of life (QoL) analysis from the randomized phase III REAL3 trial of epirubicin, oxaliplatin, and capecitabine (EOC) with or without panitumumab (P) in advanced esophagogastric adenocarcinoma.

被引：1
|
作者：
Waddell, Tom Samuel
Chau, Ian
Peckitt, Clare
Gonzalez, David
Wotherspoon, Andrew
Patel, Bijal
Middleton, Gary William
Wadsley, Jonathan
Ferry, David
Mansoor, Wasat
Crosby, Tom David Lewis
Coxon, Fareeda Y.
Smith, David
Waters, Justin S.
Iveson, Timothy
Falk, Stephen
Slater, Sarah
Okines, Alicia Frances Clare
Cunningham, David
机构：
[1] Royal Marsden NHS Fdn Trust, London, England
[2] Royal Marsden NHS Fdn Trust, Surrey, England
[3] St Lukes Canc Ctr, Guildford, Surrey, England
[4] Weston Pk Hosp, Sheffield, S Yorkshire, England
[5] New Cross Hosp, Wolverhampton, England
[6] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England
[7] Velindre Hosp NHS Fdn Trust, Cardiff, Wales
[8] Northem Ctr Canc Care, Newcastle, NSW, Australia
[9] Clatterbridge Ctr Oncol NHS Fdn Trust, Wirral, Merseyside, England
[10] Maidstone Hlth Author, Kent Oncol Ctr, Maidstone, Kent, England
[11] Canc Res UK Clin Ctr, Southampton, Hants, England
[12] Bristol Haematol & Oncol Ctr, Bristol, Avon, England
[13] Barts & London NHS Trust, London, England
[14] Royal Marsden Hosp, Sutton, Surrey, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.4067
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4067
引用
收藏
页数：1
相关论文
共 37 条
  • [21] Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer The GO2 Phase 3 Randomized Clinical Trial
    Hall, Peter S.
    Swinson, Daniel
    Cairns, David A.
    Waters, Justin S.
    Petty, Russell
    Allmark, Christine
    Ruddock, Sharon
    Falk, Stephen
    Wadsley, Jonathan
    Roy, Rajarshi
    Tillett, Tania
    Nicoll, Jonathan
    Cummins, Sebastian
    Mano, Joseph
    Grumett, Simon
    Stokes, Zuzana
    Konstantinos-Velios, Kamposioras
    Chatterjee, Anirban
    Garcia, Angel
    Waddell, Tom
    Guptal, Kamalnayan
    Maisey, Nick
    Khan, Mohammed
    Dent, Jo
    Lord, Simon
    Crossley, Ann
    Katona, Eszter
    Marshall, Helen
    Grabsch, Heike I.
    Velikova, Galina
    Ow, Pei Loo
    Handforth, Catherine
    Howard, Helen
    Seymour, Matthew T.
    JAMA ONCOLOGY, 2021, 7 (06) : 869 - 877
  • [22] ANALYSIS OF QUALITY OF LIFE (QOL) FROM THE PHASE 3 RANDOMIZED FIRST-LINE INDOLENT TRIAL IN PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA RECEIVING CONSOLIDATION THERAPY WITH 90Y-IBRITUMOMAB TIUXETAN
    D'Amore, F.
    Valderrama, A.
    Diaz, M. Gonzalez
    O'Rourke, N.
    Petrini, M.
    Sebban, C.
    Zinzani, P-L
    de Silva, M. Gomes
    Ketterer, N.
    Hagenbeek, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 319 - 320
  • [23] Safety and quality of life (QoL) findings from a randomized phase III study of capecitabine (X) plus oxaliplatin (O) (XELOX) vs. infusional 5-FU/LV + O (FOLFOX-6) in metastatic colorectal cancer (MCRC)
    Hebbar, M.
    Bennouna, J.
    Boige, V.
    Ychou, M.
    Lledo, G.
    Adenis, A.
    Faroux, R.
    Rebischung, C.
    Douillard, J.
    Conroy, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [24] Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: A gynecologic oncology group study (vol 23, pg 4617, 2005)
    Monk
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (33) : 8549 - 8549
  • [25] Final results of the FAST study, an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as first-line therapy in patients with advanced CLDN18.2+gastric and gastroesophageal junction (GEJ) adenocarcinoma
    Schuler, M.
    Al-Batran, S-E.
    Zvirbule, Z.
    Manikhas, G.
    Lordick, F.
    Rusyn, A.
    Vinnyk, Y.
    Vynnychenko, I.
    Fadeeva, N.
    Nechaeva, M.
    Dudov, A.
    Gotovkin, E.
    Pecheniy, A.
    Bazin, I.
    Bondarenko, I.
    Melichar, B.
    Huber, C.
    Tuereci, Oe.
    Sahin, U.
    ANNALS OF ONCOLOGY, 2016, 27
  • [26] ESTIMATION OF THE MINIMAL IMPORTANT DIFFERENCES IN EOSINOPHILIC ESOPHAGITIS QUALITY OF LIFE (EOE-QOL): ANALYSIS FROM A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF BUDESONIDE ORAL SUSPENSION
    Goodwin, B.
    Williams, J.
    Desai, N. K.
    Lan, L.
    VALUE IN HEALTH, 2020, 23 : S143 - S143
  • [27] Toxicity and quality of life data from SCOT: An international phase III randomized (1:1) noninferiority trial comparing 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy.
    Iveson, Timothy
    Kerr, Rachel
    Saunders, Mark P.
    Waterston, Ashita Marie
    Hollander, Niels Henrik
    Medley, Louise C.
    Tabernero, Josep
    Wilson, Charles
    Ellis, Richard
    Essapen, Sharadah
    Haydon, Andrew Mark
    Dhadda, Amandeep Singh
    Hughes, Robert
    Falk, Stephen
    Abdel-Raouf, Sherif
    Glimelius, Bengt
    Allan, Karen
    Barlow, Winnie
    Briggs, Andrew
    Paul, James
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [28] Health-related quality of life analysis from ENTER, a randomized, controlled phase III trial of whole-brain radiotherapy with and without concurrent erlotinib in NSCLC with brain metastases
    Tang, Fei
    Zhang, Jingyi
    Xu, Zaicheng
    Zhang, Yu
    Zhang, Xiaoyue
    Peng, Yuan
    Yang, Zhenzhou
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (12)
  • [29] Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial (vol 7, pg 869, 2021)
    Hall, P. S.
    Swinson, D.
    Cairns, D. A.
    JAMA ONCOLOGY, 2021, 7 (08) : 1249 - 1249
  • [30] Quality of life (QOL) analysis from the phase 3 randomized first-line indolent trial (FIT) in patients with advanced-stage follicular lymphoma receiving consolidation of first remission with 90Y-ibritumomab tiuxetan (Zevalin)
    Vitolo, U.
    Valderrama, A.
    d'Amore, F.
    Diaz, M. Gonzalez
    O'Rourke, N.
    Petrini, M.
    Sebban, C.
    Zinzani, P. L.
    Hagenbeek, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 207 - 208
1234